Atlas Capital Advisors LLC Reduces Position in IQVIA Holdings Inc. (NYSE:IQV)

Atlas Capital Advisors LLC cut its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 56.5% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 300 shares of the medical research company’s stock after selling 390 shares during the period. Atlas Capital Advisors LLC’s holdings in IQVIA were worth $63,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Team Hewins LLC increased its stake in IQVIA by 5.0% in the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock worth $246,000 after buying an additional 46 shares in the last quarter. Covestor Ltd increased its stake in IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after acquiring an additional 48 shares during the last quarter. Jag Capital Management LLC raised its holdings in shares of IQVIA by 0.4% during the 4th quarter. Jag Capital Management LLC now owns 11,401 shares of the medical research company’s stock worth $2,638,000 after acquiring an additional 49 shares in the last quarter. Continuum Advisory LLC lifted its position in IQVIA by 3.3% during the second quarter. Continuum Advisory LLC now owns 1,538 shares of the medical research company’s stock valued at $325,000 after purchasing an additional 49 shares during the last quarter. Finally, Raleigh Capital Management Inc. raised its position in shares of IQVIA by 4.5% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,157 shares of the medical research company’s stock valued at $268,000 after buying an additional 50 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of several analyst reports. UBS Group raised their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Morgan Stanley raised their price target on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, July 23rd. Robert W. Baird increased their price objective on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a research note on Tuesday, July 23rd. Truist Financial boosted their price objective on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. increased their target price on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a research report on Monday, August 5th. Five analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $265.67.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

IQVIA Price Performance

Shares of IQV opened at $251.54 on Friday. The firm has a market capitalization of $45.83 billion, a PE ratio of 34.36, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. The company’s fifty day moving average price is $231.33 and its 200-day moving average price is $234.20. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The business had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the previous year, the business posted $2.22 EPS. The business’s quarterly revenue was up 2.3% compared to the same quarter last year. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.24 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.